Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to investigate the efficacy of combined treatment with rituximab and subcutaneous cladribine in patients with newly diagnosed and relapsed chronic lymphocytic leukemia (CLL). Forty-three patients with active CLL or small lymphocytic lymphoma received rituximab 375 mg/m 2 on day 1 and cladribine 0.1 mg/kg subcutaneously on days 26. The treatment was repeated every 4 weeks for a total of four cycles. Sixteen patients were pretreated. The overall response rate was 88 (50 complete remission and 38 partial remission). The median time to treatment failure was 37.9 months. Grade 4 neutropenia developed in 5 of patients. The data indicate that combination therapy with rituximab and cladribine is a valuable and safe treatment for patients with CLL.

Original languageEnglish
Pages (from-to)1485-1493
Number of pages9
JournalLeukemia and Lymphoma
Volume51
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Chronic lymphocytic leukemia
  • rituximab
  • small lymphocytic lymphoma
  • subcutaneous cladribine

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Rituximab and subcutaneous cladribine in chronic lymphocytic leukemia for newly diagnosed and relapsed patients'. Together they form a unique fingerprint.

Cite this